Read news on response rates with our app.
Read more in the app
Pegylated interferon-based treatment improves response rates in immune-tolerant patients with chronic hepatitis B - EurekAlert!
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer - EurekAlert!
